Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.29
-0.14 (-2.18%)
At close: Apr 28, 2026, 4:00 PM EDT
6.29
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:29 PM EDT
Aligos Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 2.19 | 3.95 | 15.53 | 13.91 | 4.36 | |
| Revenue Growth (YoY) | -44.59% | -74.60% | 11.66% | 219.04% | - | |
| Cost of Revenue | 69.45 | 70.27 | 73.04 | 85.08 | 104.15 | |
| Gross Profit | -67.27 | -66.32 | -57.51 | -71.17 | -99.79 | |
| Selling, General & Admin | 20.72 | 22.83 | 29.89 | 26.41 | 28.53 | |
| Operating Expenses | 20.72 | 22.83 | 29.89 | 26.41 | 28.53 | |
| Operating Income | -87.99 | -89.15 | -87.4 | -97.58 | -128.32 | |
| Interest & Investment Income | 2.16 | 1.67 | 4.3 | 1.52 | 0.24 | |
| Currency Exchange Gain (Loss) | 0.2 | - | -0.05 | -0.04 | -0.01 | |
| Other Non Operating Income (Expenses) | 61.74 | -43.4 | -3.01 | 0.16 | -0.1 | |
| EBT Excluding Unusual Items | -23.88 | -130.88 | -86.16 | -95.94 | -128.19 | |
| Asset Writedown | - | - | -0.72 | - | - | |
| Pretax Income | -23.88 | -130.88 | -86.88 | -95.94 | -128.19 | |
| Income Tax Expense | 0.31 | 0.33 | 0.8 | 0.11 | 0.14 | |
| Net Income | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 | |
| Net Income to Common | -24.19 | -131.21 | -87.68 | -96.05 | -128.33 | |
| Shares Outstanding (Basic) | 10 | 6 | 3 | 2 | 2 | |
| Shares Outstanding (Diluted) | 10 | 6 | 3 | 2 | 2 | |
| Shares Change (YoY) | 57.79% | 144.38% | 50.10% | 7.12% | 299.03% | |
| EPS (Basic) | -2.45 | -20.94 | -34.20 | -56.24 | -80.50 | |
| EPS (Diluted) | -2.45 | -20.94 | -34.20 | -56.25 | -80.50 | |
| Free Cash Flow | -82.94 | -80.87 | -79.02 | -80.33 | -116.55 | |
| Free Cash Flow Per Share | -8.39 | -12.91 | -30.82 | -47.04 | -73.11 | |
| Operating Margin | -4024.93% | -2259.92% | -562.84% | -701.66% | -2943.82% | |
| Profit Margin | -1106.72% | -3326.01% | -564.62% | -690.63% | -2944.07% | |
| Free Cash Flow Margin | -3794.15% | -2050.01% | -508.83% | -577.64% | -2673.87% | |
| EBITDA | -87.06 | -88.13 | -85.84 | -95.27 | -125.3 | |
| D&A For EBITDA | 0.93 | 1.03 | 1.56 | 2.31 | 3.02 | |
| EBIT | -87.99 | -89.15 | -87.4 | -97.58 | -128.32 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.